Literature DB >> 21167338

Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: results from the Occluded Artery Trial (OAT).

Gerard Devlin1, Harmony R Reynolds, Daniel B Mark, James M Rankin, Antonio C Carvalho, Carlos Vozzi, George Sopko, Paulo Caramori, Vladimir Džavík, Michael Ragosta, Sandra A Forman, Gervasio A Lamas, Judith S Hochman.   

Abstract

BACKGROUND: the OAT found that routine late (3-28 days post-myocardial infarction) percutaneous coronary intervention (PCI) of an occluded infarct-related artery did not reduce death, reinfarction, or heart failure relative to medical treatment (MED). Angina rates were lower in PCI early, but the advantage over MED was lost by 3 years.
METHODS: angina and revascularization status were collected at 4 months, then annually. We assessed whether non-protocol revascularization procedures in MED accounted for loss of the early symptomatic advantage of PCI.
RESULTS: seven per 100 more PCI patients were angina-free at 4 months (P < .001) and 5 per 100 at 12 months (P = .005) with the difference narrowing to 1 per 100 at 3 years (P = .34). Non-protocol revascularization was more frequent in MED (5-year rate 22% vs 19% PCI, P = .05). Indications for revascularization included acute coronary syndromes (39% PCI vs 38% MED), stable angina/inducible ischemia (39% in each group), and physician preference (17% PCI vs 15% MED). Revascularization rates among patients with angina at any time during follow-up (35% of cohort) did not differ by treatment group (5-year rates 26% PCI vs 28% MED). Most symptomatic patients were treated without revascularization during follow-up (77%).
CONCLUSIONS: in a large randomized clinical trial of stable post-myocardial infarction patients, the modest benefit on angina from PCI of an occluded infarct-related artery was lost by 3 years. Revascularization was slightly more common in MED during follow-up but was not driven by acute ischemia, and almost 1 in 5 procedures were attributed to physician preference alone.

Entities:  

Mesh:

Year:  2011        PMID: 21167338      PMCID: PMC3004529          DOI: 10.1016/j.ahj.2010.09.009

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  19 in total

1.  Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE).

Authors:  Kim A Eagle; Shaun G Goodman; Alvaro Avezum; Andrzej Budaj; Cynthia M Sullivan; José López-Sendón
Journal:  Lancet       Date:  2002-02-02       Impact factor: 79.321

2.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Authors:  Steven R Steinhubl; Peter B Berger; J Tift Mann; Edward T A Fry; Augustin DeLago; Charles Wilmer; Eric J Topol
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

3.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

4.  Angina at 1 year after myocardial infarction: prevalence and associated findings.

Authors:  Thomas M Maddox; Kimberly J Reid; John A Spertus; Murray Mittleman; Harlan M Krumholz; Susmita Parashar; P Michael Ho; John S Rumsfeld
Journal:  Arch Intern Med       Date:  2008-06-23

5.  Quality of life after late invasive therapy for occluded arteries.

Authors:  Daniel B Mark; Wenqin Pan; Nancy E Clapp-Channing; Kevin J Anstrom; John R Ross; Rebecca S Fox; Gerard P Devlin; C Edwin Martin; Christopher Adlbrecht; Patricia A Cowper; Linda Davidson Ray; Eric A Cohen; Gervasio A Lamas; Judith S Hochman
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

6.  A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators.

Authors:  A F Parisi; E D Folland; P Hartigan
Journal:  N Engl J Med       Date:  1992-01-02       Impact factor: 91.245

7.  Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial.

Authors:  Marc Cohen; Gian Franco Gensini; Frans Maritz; Enrique P Gurfinkel; Kurt Huber; Ari Timerman; Maria Krzeminska-Pakula; Jose Santopinto; Carole Hecquet; Luc Vittori
Journal:  Circulation       Date:  2003-10-21       Impact factor: 29.690

8.  Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy.

Authors:  Robert A Henderson; Stuart J Pocock; Tim C Clayton; Rosemary Knight; Keith A A Fox; Desmond G Julian; Douglas A Chamberlain
Journal:  J Am Coll Cardiol       Date:  2003-10-01       Impact factor: 24.094

9.  Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial.

Authors:  Vladimír Dzavík; Christopher E Buller; Gerard Devlin; Ronald G Carere; G B John Mancini; Warren J Cantor; Pawel E Buszman; James M Rankin; Carlos Vozzi; John R Ross; Sandra Forman; Bruce A Barton; A Gervasio A Lamas; Judith S Hochman
Journal:  Catheter Cardiovasc Interv       Date:  2009-05-01       Impact factor: 2.692

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  1 in total

1.  Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction.

Authors:  Judith S Hochman; Harmony R Reynolds; Vladimír Dzavík; Christopher E Buller; Witold Ruzyllo; Zygmunt P Sadowski; Aldo P Maggioni; Antonio C Carvalho; James M Rankin; Harvey D White; Suzanne Goldberg; Sandra A Forman; Daniel B Mark; Gervasio A Lamas
Journal:  Circulation       Date:  2011-10-24       Impact factor: 29.690

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.